Preissner K T
Haemostasis Research Unit, Kerckhoff-Klinik, MPG, Bad Nauheim, Germany.
Thromb Haemost. 1993 May 3;69(5):422-9.
During the reaction of antithrombin III (AT III) with target proteases the inhibitor serves as pseudo-substrate and undergoes profound conformational changes, becomes incorporated into a covalent stoichiometric enzyme-inhibitor complex which is, in contrast to native AT III, recognized by monoclonal antibody 4C9. In the absence of the target enzyme thrombin, incubation of AT III with 1-2 M guanidine, 0.6% deoxycholate, heating to 56 degrees C, or buffer at pH 4 resulted in inactivation of the inhibitor with concomitant exposure of the epitope for 4C9 and formation of AT III multimers (from 3.9 S to 7.1-7.4 S). Loss of activity, formation of multimers and exposure of neoepitope(s) of AT III occurred in a concerted fashion and followed second order kinetics with an activation energy of Ea = 31 kcal/mol. AT III-multimerization induced by treatment with 1 M guanidine (mainly AT III-tetramers with M(r) of 250,000) and formation of the binary AT III-thrombin complex revealed similar self-association patterns as judged by gel electrophoresis under non-denaturing conditions. In the presence of heparin, even higher multimers of AT III-thrombin complexes were noted. Moreover, self-association products of the ternary vitronectin-thrombin-AT III complex, which is the ultimate reaction product following thrombin inhibition in the circulation, could be recognized and quantitated due to exposure of the 4C9 epitope on AT III, indicating that AT III exists in multimeric forms within binary and ternary complexes.(ABSTRACT TRUNCATED AT 250 WORDS)
在抗凝血酶III(AT III)与靶蛋白酶的反应过程中,该抑制剂充当假底物并经历深刻的构象变化,形成共价化学计量的酶 - 抑制剂复合物,与天然AT III不同,该复合物可被单克隆抗体4C9识别。在没有靶酶凝血酶的情况下,将AT III与1 - 2 M胍、0.6%脱氧胆酸盐一起孵育、加热至56℃或置于pH 4的缓冲液中,会导致抑制剂失活,同时暴露4C9的表位并形成AT III多聚体(从3.9 S到7.1 - 7.4 S)。AT III的活性丧失、多聚体形成和新表位暴露以协同方式发生,并遵循二级动力学,活化能Ea = 31 kcal/mol。用1 M胍处理诱导的AT III多聚化(主要是分子量为250,000的AT III四聚体)以及二元AT III - 凝血酶复合物的形成,在非变性条件下通过凝胶电泳判断显示出相似的自缔合模式。在肝素存在下,注意到AT III - 凝血酶复合物有更高的多聚体。此外,由于AT III上4C9表位的暴露,可以识别和定量三元玻连蛋白 - 凝血酶 - AT III复合物的自缔合产物,该复合物是循环中凝血酶抑制后的最终反应产物,表示AT III以多聚体形式存在于二元和三元复合物中。(摘要截短于250字)